伊德本对患有amnestic轻度认知障碍的患者的认知功能和血清生物标志物的影响
Huiting Wang1,2, Xiaoling Wang1, Weiwei Wang3
1Department of Neurology, Liaocheng People's Hospital, No. 67 Dongchang West Road, Liaocheng, 252000, Shandong Province, People's Republic of China.
European journal of medical research
|December 19, 2024
概括
伊德本显著改善了认知功能,特别是延迟回忆,在患有amnestic轻度认知障碍 (aMCI) 的个体中. 治疗还减少了炎症和氧化应激,表明idebenone作为一个有前途的干预 aMCI.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- Amnestic 轻度认知障碍 (aMCI) 的特点是记忆力缺陷.
- 氧化应激和炎症与aMCI的进展有关.
研究的目的:
- 评估idebenone在改善aMCI患者的认知功能方面的疗效.
- 评估伊德本对氧化应激 (超氧化脱酶,SOD) 和炎症 (高灵敏性C反应蛋白,hs-CRP) 的血清生物标志物的影响.
主要方法:
- 对aMCI患者接受idebenone治疗的回顾性研究 (每天三次服用30毫克6个月).
- 选择了51名不接受认知增强剂的MCI患者的对照组.
- 在治疗前和治疗后评估认知功能 (MoCA,延迟回忆) 和血清生物标志物.
主要成果:
- 治疗idebenone导致MoCA得分显著改善,并延迟了回忆.
- 血清SOD水平增加,而hs-CRP水平在治疗后下降.
- 在对照组中没有观察到任何显著的变化.
结论:
- 在患有MCI的个体中,Idebenone有效地提高了认知功能,特别是记忆力.
- 伊德本显示出抗炎和抗氧化作用.
- 伊德本显示出作为管理MCI的治疗剂的潜力.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162


